The effectiveness of malaria camps as part of the malaria control program in Odisha, India

Study population and study design

Fifteen villages were selected in the northern districts of Keonjhar and Jharsuguda in Odisha state, India, in consultation with the Odisha Malaria Control Program (Figure 1). The villages were distributed between three study arms: six villages in Arm A ‘new-MC’ (communities receiving MCs for the first time in year one), six villages in Arm B ‘delayed-MC’ (communities undergoing routine malaria control in year one and receiving MCs for the first time in year two), and three villages in Arm C ‘old-MC’ villages, where MCs had already been implemented prior to the study period. A flow chart of the study is shown in Figure 2.

• Download figure
• Open in new tab

Figure 1. Location of 15 hard-to-reach villages in Odisha, India.

The two DHH (district headquarter hospitals) are indicated, and each village is named with its study arm letter (A, B, C) and village number (V1-15) provided. Maps created with Google©2023, INEGI.

• Download figure
• Open in new tab

Figure 2. Cluster-assigned quasi-experimental study of malaria camps as part of the DAMaN malaria elimination program in Odisha, India.

Flow chart providing a summary of the 15 clusters (villages) distributed between three arms, and sampled at baseline and three follow-ups. A timeline of the activities is also given, and whether COVID-19 shutdowns are known to have occurred.

We enrolled 2463 participants in the study and Table 1 presents their baseline demographic characteristics. A total of 14% of the participants was aged 5 years or younger, 29.4% were aged 6 to 17, 23.6% were 18-35, and 32.9% were over age 35, with females comprising 56.1% of the participants. The participants generally had low educational attainment: almost half (49.4%) had no schooling/less than primary school whereas 5.6% had higher secondary school or more. With respect to occupation, 28.8% were housewives, 34.9% were students, 5.6% were farmers/agricultural laborers, 18.5% were employed in another trade, 9.6% were children that were not in school, and 2.6% did not have an occupation.

Across the study arms there were significant differences in age, educational attainment, and occupation, but not sex. As evidenced by the age category distribution and the mean age for each arm, Arm A was older (mean age [M_age]=27.2, standard deviation [SD]=19.0) and Arm C was younger (M_age=22.2, SD=18.8) than Arm B (M_age = 25.7, SD = 19.6, p_ANOVA<0.001). A higher proportion of participants in Arm A had higher secondary education or higher while a higher proportion in Arm B had middle, secondary, or matric and in Arm C a high proportion had primary education. There were a higher proportion of farmers/agricultural laborers and people with other employment/trades in Arm A, a higher proportion of housewives in Arm B, and higher proportions of students and children not in school in Arm C. Given the differences across arms, adjusted odds ratios (aORs) control for demographics.

Intent-to-treat analysis for primary and secondary malaria outcomes

The MC intervention was revised from our initial protocol paper⁷ with two major and consistent differences. First, all MCs conducted MSAT rather than FSAT in all rounds of the intervention. Second, LLINs were not distributed in our study villages because their 3-yearly replenishment distribution scheduled for 2020 was delayed due to the Covid-19 pandemic.

Table 1 presents the malaria outcomes at baseline and the third follow-up visit; associations are considered significant if p<0.013. At baseline, 9.9% of the sample had PCR+ Plasmodium infection, with significant differences across study arms. Arm A had the highest prevalence of Plasmodium infection (14.2%), followed by Arm B (8.1%) and Arm C (3.9%, p<0.001). Prevalence of RDT+ Plasmodium infection was 1.9% and there were no significant differences across arms; Arm A again had the highest prevalence of Plasmodium infection (2.7%), followed by Arm B (1.8%) and Arm C (0.5%, p=0.014). When malaria was defined by any positive PCR or RDT test, prevalence overall was 9.9% at baseline. With respect to species, 236 (98.3%) were P. falciparum cases and 9 (3.8%) were P. vivax; 5 (2.1%) were co-infected with P. falciparum and P. vivax [data not shown]. Approximately 48.3% of malaria infections were asymptomatic (defined as RDT+ or PCR+ and no fever) at baseline with Arm C having the highest proportion (94.7%) of asymptomatic cases as compared to Arms A and B (40.4 and 52.4%, respectively; p<0.001). A substantial majority (80.3%) of malaria cases were subpatent (i.e., RDT- and PCR+), with no significant differences across arms.

At the third follow-up visit, 2.6% of the sample had PCR+ Plasmodium infection, with no significant differences across arms. Prevalence of RDT+ Plasmodium infection was 0.9% overall at follow-up, with 0.5% prevalence in Arm A, 1.7% prevalence in Arm B, and no observed cases in Arm C (p=0.005). When malaria was defined by any positive PCR or RDT test, prevalence overall was 2.8% at baseline. When we compared malaria outcomes from baseline to follow-up for the entire sample as well as each arm, we found that there was a significant reduction in both RDT+ and PCR+ Plasmodium infection in the sample overall and for Arm A. We observed a significant reduction in PCR+ but not RDT+ Plasmodium infection in Arm B and no significant differences in Arm C. With respect to species, 236 (98.3%) were P. falciparum cases and 9 (3.8%) were P. vivax; 5 (2.1%) were co-infected with P. falciparum and P. vivax [data not shown]. Approximately 85.7% of malaria infections were asymptomatic at FU3 with no significant differences across arms but significant increases in the proportion of cases that were asymptomatic from baseline to FU3 for the entire sample (p<0.001), Arm A (p=0.002), and Arm B (p<0.001) but not Arm C. A substantial majority (68.4%) of malaria cases were subpatent at FU3, with a significant decrease from baseline to FU3 in Arm B only (78.1 to 56.3%, p=0.035).

The overall follow-up rate for FU3 was 81.5% with a range of 81.5 to 83.4% across arms, with no significant differences across arms (Table 1). The sociodemographic and malaria outcome correlates of participants lost-to-follow-up is shown in Table 2.

There were no significant differences in loss-to-follow-up (LTFU) by study arm or sex. Younger people were more likely to be LTFU as were those with lower educational attainment, students, and children not in school. Those with malaria, regardless of detection method, were significantly more likely to be LTFU but there were no significant differences by asymptomatic or subpatent cases.

Table 3 presents the crude and adjusted multilevel mixed effects logistic regression models for the primary and secondary malaria outcomes. The adjusted models controlled for age and gender given baseline differences in demographics across study arms. Education and occupation were not included in the model, although they were significant in the bivariate analyses, due to multicollinearity. For the primary outcome of PCR-positive Plasmodium infection, the adjusted model shows almost five-fold higher odds for PCR+ Plasmodium infection at baseline in Arm A (new MC, adjusted OR [AOR]=5.96, 95% confidence interval [CI] = 1.04, 23.59) but not Arm C (old MC) as compared to Arm B (delayed MC). Across all three arms, the odds of PCR+ Plasmodium infection were 54% lower at follow-up compared to baseline (95% CI = 0.23, 0.63). The time (i.e., baseline vs. FU3) x study arm interaction term shows that there were significantly lower odds of PCR+ Plasmodium infection in Arm A (AOR = 0.36, 95% CI = 0.17, 0.73) but not Arm C as compared to Arm B at follow-up. The adjusted model for PCR+ or RDT+ Plasmodium infection showed similar results. For RDT+ Plasmodium infection, there were no significant differences in the odds of Plasmodium infection at baseline or follow-up across arms. The time x study arm interaction term shows that there were significantly lower odds of PCR+ Plasmodium infection in Arm A (AOR = 0.17, 95% CI = 0.04, 0.70) as compared to Arm B at follow-up. An odds ratio for Arm C at follow-up was not calculated because there were no RDT+ Plasmodium infections at follow-up in Arm C.

Intent-to-treat analysis for secondary outcomes

The anthropometric and clinical outcomes at baseline and the third follow-up visit are shown in Table 4; associations are considered significant if p<0.013. At baseline, 33.3% were severely underweight, with no differences across study arms. At follow-up, the prevalence of severe underweight increased to 36.8%, but this increase was not significant; there were still no differences across arms in underweight at follow-up. Few (2.2%) were severely anemic, with significantly more anemia in Arm A (5.1%) as compared to Arms B and C (0.1 and 0.7%, respectively; p<0.001). At follow-up there were no significant differences in anemia across arms, but there were significant decreases from baseline to follow-up for the total sample and Arm A. At baseline, prevalence of fever was 24.3%. Arm B had the highest prevalence (38.1%) as compared to Arm A (14.6%) and Arm C (13.9%, p<0.001). There were no significant differences in fever across arms at follow-up, although there were significant reductions from baseline to follow-up overall and for each arm (p<0.001). Prevalence of malnutrition measured by MUAC was 19.3% at baseline, with higher prevalence in Arm C (26.4%) as compared to Arms A (18.2%) and B (17.2%, p<0.001). At follow-up there were significant differences in malnutrition across arms but no significant differences from baseline to follow-up. Crude and adjusted multilevel mixed effects logistic regression models were not estimated for these secondary outcomes due to small numbers (i.e., severe anemia and fever) and/or few significant differences in the bivariate analyses comparing baseline to follow-up (i.e., severe underweight, severe anemia, MUAC malnutrition).

Pfhrp2 deletion prevalence in study sample

From a total of 2,463 individuals enrolled in our baseline survey across all study arms, 240 (9.7%) were infected with Plasmodium as detected by RDT and/or PCR at baseline, and 192 (80%) of those were RDT-/PCR+ (i.e., subpatent). Because the prevalence of subpatent infections was so high, we undertook assays to determine whether there were deletions of the pfhrp2 gene among the cases. Pfhrp2 deletions are a major contributor to RDT failures both globally¹¹ and in the Odisha region^{12, 13, 14}, since most of the commercially available RDTs detect histidine-rich protein 2 (HRP2) which is produced during the asexual blood stage of P. falciparum infection.

Of the n=113 fever positive RDT-/PCR+ infections from the baseline survey, 95 (84.1%) were pfhrp2 negative, 2 (1.8%) were pfhrp2 positive, and 13 (11.5%) were inconclusive (Table 5). An additional 79 P. falciparum RDT-/PCR+ fever negative baseline infections were tested: 41 (51.9%) were pfhrp2 negative and 32 (40.5%) were pfhrp2 positive. A total of n=62 RDT- /PCR+ infections were identified across the FU1, FU2, and FU3 surveys, of which 19 (30.7%) were pfhrp2 negative and 40 (64.5%) were pfhrp2 positive.

Malaria exposure and serology in a subset of study participants

We assayed 300 baseline samples (240 PCR+ and 60 PCR-) for anti-Plasmodium antibodies to 13 P. falciparum-specific antigens and four P. vivax-specific antigens using the Luminex MAGPIX platform and xPONENT software to estimate mean fluorescence intensity (MFI). Data were missing for six markers (n=180 missing for PvMSP10; n=20 missing for PfEBA140 R3-5, PfETRAMP5_ag1, PfMSP2CH150, PfRh2_2030, and PvMSP8). There were no significant differences by gender for P. falciparum and P. vivax antibodies, but the proportion positive increased as age increased (data not shown).

Table 6 summarizes the antibody results by study arm and infection status. There were no significant differences between Arms A and B in terms of P. falciparum and/or P. vivax antibodies at baseline. There were significant differences in antibodies across all three arms, with a lower proportion of Arm C participants having Plasmodium antibodies. With respect to baseline infection status, a higher proportion of symptomatic participants had P. falciparum antibodies as compared to uninfected and asymptomatic participants. A higher proportion of asymptomatic participants had P. vivax antibodies as compared to uninfected and infected participants.

Village-level costs of MCs

We conducted an analysis of the implementation costs of MCs in the study villages from the service provider perspective. The results of the cost analysis are presented in Table 7.

In the study villages, the cost per person ranged between US$3-8, the cost per tested between US$4-7, and the cost per treated between US$82-1,614 per camp round.

Ethics statement

Ethical approval for the trial was obtained from the Odisha State Research and Ethics Committee (Odisha, India), institutional ethics committee at Community Welfare Society Hospital (Rourkela, Odisha, India) and the institutional review board at New York University (New York, NY, USA). All research was performed in accordance with relevant guidelines/regulations and the Declaration of Helsinki.

Study design and enrollment procedures

The quasi-experimental cluster-assigned stepped-wedge study design, power analysis, and recruitment/enrollment procedures are described in a protocol paper⁷ and the study was registered at ClinicalTrials.gov (NCT03963869). Briefly, 12 intervention villages were selected in two districts of Odisha state, Keonjhar and Jharsuguda, and distributed in equal numbers between two study arms: Arm A ‘new-MC’ (communities receiving MCs for the first time in year one) and Arm B ‘delayed-MC’ (communities undergoing routine malaria control in year one and receiving MCs for the first time in year two); control Arm C contained three ‘old-MC’ villages, where MCs had already been implemented prior to the study period. A cohort was planned with target enrollment of 2,700 individuals across all 15 villages (i.e., 1100 in Arms A and B; 500 in Arm C).

Study participants in each village were recruited and enrolled at baseline before the initial administration of the intervention and subsequently surveyed prior to each round of screen and treat by the Government of Odisha DAMaN team. Study participants in the three villages not receiving the intervention were recruited and enrolled in parallel temporally. Residents of the study villages aged 1 to 69 were eligible for the study. Written informed consent was obtained in the local language from all adult study participants aged 18-69 years with apparent full comprehension of the study procedures. Assent was obtained in addition to parental or legal guardian informed consent for participants aged 7-17 years. Parental informed consent was obtained for children aged 1-6 years. During each survey round, all subjects completed a health questionnaire that captured demographic, malaria knowledge and prevention, and malaria infection and treatment history data, and provided a blood sample for Plasmodium parasite detection.

Intervention adaptations due to COVID-19 pandemic

Arm A (new MC) and C (old MC) villages were to receive two cycles of MCs, each with two rounds of MSAT. The first MC cycle was from August to November 2019 (Round 1) and January to March 2020 (Round 2). We note that the Round 2 MSAT was interrupted by COVID-19 pandemic shutdowns. The second MC cycle was from June to September 2020 (Round 1) and October to December 2020 (Round 2). We note that Round 1 MSAT was also interrupted by COVID-19 pandemic shutdowns. Arm B (delayed MC) villages were to receive SOC in the first cycle (August 2019 – March 2020) and one MC cycle with two rounds of MSAT from June to September 2020 (Round 1) and October to December 2020 (Round 2). Again, Round 1 was interrupted by the pandemic.

Primary outcomes

The primary outcome measures were any Plasmodium as detected by PCR and Plasmodium species (i.e., P. falciparum and/or Plasmodium vivax) as detected by PCR. Secondary malaria outcome measures included Plasmodium infection as detected by RDT and Plasmodium-specific serology. Plasmodium infection by RDT is defined as RDT negative (RDT-) or RDT positive (RDT+). We further classified infections as ‘asymptomatic’, defined as PCR+ and/or RDT+ for any Plasmodium species with absence of documented fever or self-reported fever in the last 48 hours, and/or ‘subpatent’, defined as RDT- and PCR+. Plasmodium-specific serology was analyzed as a continuous antibody titer variable as well as a categorical (seropositive vs. seronegative) variable.

Blood sample collection and processing

Blood samples for blood smears, blood spots (Whatman FTA cards), a small volume microvette, and micro volumes required for point of care hemoglobin and RDTs, were collected from consenting study participants by sterile lancet finger prick as previously described⁷. Vacutainers (5 ml; BD Vacutainer glass blood collection tubes with acid citrate dextrose) of venous blood were requested from study participants found to be positive by RDT. Microvette and vacutainer samples were refrigerated until separated into plasma and infected red blood cell (iRBC) components by centrifugation. Plasma was stored at - 80°C until assayed for Plasmodium immunoglobulin G (IgG), and total DNA was extracted from the iRBC pellet using QIamp DNA mini kit (QIAGEN) with a final elution volume of 50 μl.

Molecular detection of Plasmodium parasites by species-specific PCR

DNA samples were tested for Plasmodium species by a PCR assay targeting multi-copy loci Pfr364 and Pvr47²⁰ as previously described⁷. Five μl of DNA was used in a total reaction volume of 30 μl, and amplification products were visually confirmed by ethidium bromide-stained gel electrophoresis using a Gel Doc EZ documentation system (BioRad Laboratories, Inc.).

Detection of anti-Plasmodium IgG by Luminex MAGPIX cytometric bead array

Plasma isolated from a subset of microvette samples of finger prick blood was assayed for 13 anti-P. falciparum and four anti-P. vivax antibodies as previously described.⁷ The panel included antigens whose corresponding antibodies have been suggested as indicators of protection from clinical disease^{21, 22}, long-term or cumulative exposure^{23, 24, 25, 26}, and recent infection^{23, 24, 25, 26}. Briefly, n=300 plasma samples were diluted 1/200 and assayed in duplicate according to standard procedures^{27, 28}. xPONENT software was used for data acquisition (Luminex Corp., Austin, TX). Specifically, the net Mean Fluorescence Intensity (MFI; net MFI_Ag = raw MFI_Ag - background MFI_Ag where background MFI_Ag is the mean MFI of a given antigen in the blank wells) was calculated for each antigen in each sample. The presence of antibody to each antigen (e.g., seropositivity) was defined as the mean net MFI_{naive pool} plus three standard deviations. Composite variables for any P. falciparum, any P. vivax, and any P. falciparum or P. vivax antibodies were created.

Secondary anthropometric and clinical outcomes

We report on several anthropometric measurements, including severe underweight, severe anemia, fever, and malnutrition as measured by mid-upper arm circumference (MUAC). For adults aged 18 and older, severe underweight was defined as a BMI<16. For children, severe underweight was defined as three standard deviations below the median based on the WHO growth charts used for children <5 years and the revised Indian Academy of Pediatrics (IAP) growth charts for Indian children and adolescents aged 5 to 17²⁹. Severe anemia was defined as hemoglobin <5 g/dl for persons aged <12 and 7 g/dl among those aged 12 and older³⁰. Fever was defined as a temperature of 99.5°F or higher. MUAC malnutrition was defined as <23 cm for adults and adolescents aged 15 and older^{31, 32}, <16 cm for 10-14 year olds³³, <12.9 cm for 5-9 year olds³³, and <11.5 cm for children 6 to 60 months³⁴.

Identification of pfhrp2 gene deletions

DNA extracted from microvette samples from RDT- /PCR+ individuals across all survey rounds were evaluated for pfhrp2 gene deletions using a multi-step workflow modified from Bharti et al., and Baker et al.,^{12, 13}. Briefly, the workflow consisted of (1) conventional PCR targeting pfhrp2 exon 2 of all RDT-/PCR+ samples, (2) nested PCR targeting pfhrp2 exon 1-2 of all pfhrp2 exon 2 positive samples, (3) nested PCRs targeting the upstream and downstream flanking regions of all pfhrp2 exon 1-2 positive samples, and (4) a DNA sample quality control confirmation qPCR of pfhrp2 exon 2, exon 1-2, and/or flanking region negative samples using screening of the Pf aldolase gene. A total of n=271 RDT-/PCR+ DNA samples were evaluated.

Costing study design, data collection, and analyses

Using an activity-based costing method, we conducted an analysis of the implementation costs of malaria camps (MCs) in the study villages from the service provider perspective.³⁵ Interviews were conducted with the malaria camp supervisors who led the MCs in the study villages, and programmatic documentation from the Odisha State malaria control program were reviewed to identify the activities related to the planning and implementation of DAMaN at the village-level. These included: (1) Training activities (training of public health supervisors and workers as well as village volunteers, including the village specific ASHAs; (2) Micro-plan development for MCs; (3) Planning and sensitization activities (identification of village volunteers, selection of camp venue and time); (4) Community sensitization activities; (5) Community mobilization activities; (6) Health activities (malaria testing and treatment, child health, maternal health); (7) Monitoring and supervision activities; and (8) Follow-up activities. Resource use was linked to specific activities associated with an intervention. During interviews, the MC supervisors identified the time dedicated by MC staff to different activities for each camp round. Time costs of MC staff were calculated based on average annual gross wage rates, apportioned according to time devoted to DAMaN activities per camp round, and summed across all MC staff. Unit costs of rapid diagnostic kits and antimalarial drugs were extracted from the DAMaN Operational Guidelines³⁶. The costs of these commodities were calculated by multiplying the quantities used during a camp round by their unit costs based on participation in each camp round in a given village. Personnel and implementation costs per round were summed and divided by the population that participated in the MC, the population tested for malaria, and the population treated for malaria, in each study village to calculate cost per person, cost per person tested, and cost per person treated per camp round. All costs were collected in local currency and converted to and presented in 2020 US dollars (US$), using the average exchange rate for 2020 (1 US$ = 74.27 Indian Rupees)³⁷.

Statistical analyses

The primary outcome was Plasmodium presence and species as detected by PCR at the third follow-up visit. Secondary outcomes included Plasmodium presence and species as detected by RDT and anthropometric and clinical outcomes including underweight, anemia, fever, and malnutrition as measured by mid-upper arm circumference (MUAC) at the third follow-up visit. Missing data was minimal among the analytic sample and ranged from 0 to 1.5% depending on the variable.

Bivariate analyses compared outcomes and key covariates across study arms with Pearson’s χ² or Fishers exact tests (if cell sizes were <5) at baseline and outcomes at follow-up 3. We use a Bonferroni adjusted α of 0.013 to account for multiple comparisons in the bivariate analyses comparing baseline to follow-up outcomes. Follow-up rates were calculated as the proportion of baseline participants that were followed up at the third time point.

Multilevel mixed-effects logistic regression was used to estimate the intervention effects, which enabled us to account for the repeated measure and nesting of individuals within the 15 villages. An interaction term (study arm x visit [baseline vs. FU3]) was used to estimate time effects for each arm and village was included as a random effect. We first estimated the crude associations for each outcome by study arm. We then adjusted these estimates for age, sex, education, and occupation. Odds ratios with 95% confidence intervals are reported. All analyses were conducted with Stata 17.0 (StataCorp, College Station, TX, USA) and were intent-to-treat. The study was registered at ClinicalTrials.gov (#NCT03963869).